Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T, et al. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. 10.1515/raon-2017-0008ZadnikVPrimic ZakeljMLokarKJarmKIvanusUZagarTCancer burden in Slovenia with the time trends analysisRadiol Oncol201751475510.1515/raon-2017-0008Open DOISearch in Google Scholar
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol 2010; 28: 2181-90. 10.1200/JCO.2009.26.2543AupérinALe PéchouxCRollandECurranWJFuruseKFournelPMeta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancerJ Clin Oncol20102821819010.1200/JCO.2009.26.2543Open DOISearch in Google Scholar
Pless M, Stupp R, Ris H-B, Stahel RA, Weder W, Thiersteinet S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386: 1049-56. 10.1016/S0140-6736(15)60294-XPlessMStuppRRisH-BStahelRAWederWThiersteinetSInduction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialLancet201538610495610.1016/S0140-6736(15)60294-XOpen DOISearch in Google Scholar
Eberhardt WEE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrichet V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33: 4194-201. 10.1200/JCO.2015.62.6812EberhardtWEEPöttgenCGaulerTCFriedelGVeitSHeinrichetVPhase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)J Clin Oncol201533419420110.1200/JCO.2015.62.6812Open DOISearch in Google Scholar
Bradley JD, Paulus R, Komaki R, Masters G, Blumenscheinet G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 2015; 16: 187-99. 10.1016/S1470-2045(14)71207-0BradleyJDPaulusRKomakiRMastersGBlumenscheinetGSchildSStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial pLancet Oncol2015161879910.1016/S1470-2045(14)71207-0Open DOISearch in Google Scholar
Garon EB, Naiyer AR, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824GaronEBNaiyerARHuiRLeighlNBalmanoukianASEderJPPembrolizumab for the treatment of non–small-cell lung cancerN Engl J Med201537220182810.1056/NEJMoa1501824Open DOISearch in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627BrahmerJReckampKLBaasPCrinòLEberhardtWEEPoddubskayaENivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancerN Engl J Med20153731233510.1056/NEJMoa1504627Open DOISearch in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAPembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancerN Engl J Med201637518233310.1056/NEJMoa1606774Open DOISearch in Google Scholar
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895-903. 10.1016/S1470-2045(17)30380-7ShaverdianNLisbergAEBornazyanKVeruttipongDGoldmanJWFormentiSCPrevious radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialLancet Oncol20171889590310.1016/S1470-2045(17)30380-7Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. 10.1056/NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancerN Engl J Med201737719192910.1056/NEJMoa170993728885881Open DOISearch in Google Scholar
Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non–small-cell lung cancer: a southwest oncology group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-60. 10.1200/JCO.2002.03.055AlbainKSCrowleyJJTurrisiATGandaraDRFarrarWBClarkJIConcurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non–small-cell lung cancer: a southwest oncology group phase II study, SWOG 9019J Clin Oncol20022034546010.1200/JCO.2002.03.055Open DOISearch in Google Scholar
National Institute of Cancer. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events v3.0 (CTCAE). [cited 2017 Nov 2]. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. NIH Publ2010; 2009: 0-71. 10.1080/00140139.2010.489653National Institute of Cancer. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events v3.0 (CTCAE)[cited 2017 Nov 2]. Available athttp://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfNIH Publ2010200907110.1080/00140139.2010.489653Open DOISearch in Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205-16. 10.1093/jnci/92.3.205TherassePArbuckSGEisenhauerEAWandersJKaplanRSRubinsteinLNew guidelines to evaluate the response to treatment in solid tumorsJNCI2000922051610.1093/jnci/92.3.205Open DOISearch in Google Scholar
Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma 2018; 59: 101-6. 10.4149/neo_2018_170206N77VrankarMZwitterMKernIStanicK.PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapyNeoplasma201859101610.4149/neo_2018_170206N77Open DOISearch in Google Scholar
Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-86. 10.1016/S0140-6736(09)60737-6AlbainKSSwannRSRuschVWTurrisiATShepherdFASmithCRadiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialLancet20093743798610.1016/S0140-6736(09)60737-6Open DOISearch in Google Scholar
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et
al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. AnnOncol 2017; 28 (Suppl 4): iv1-21. 10.1093/annonc/mdx222PostmusPEKerrKMOudkerkMSenanSWallerDAVansteenkisteJEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Ann Oncol2017284iv12110.1093/annonc/mdx22228881918Open DOISearch in Google Scholar
Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.KovačVSmrdelU.Meta-analyses of clinical trials in patients with non-small cell lung cancerNeoplasma20045133440Search in Google Scholar
Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non–small-cell lung cancer?: A pooled analysis of the literature. J Thorac Oncol 2013; 8: 1181-9. 10.1097/JTO.0b013e3182988348TsujinoKKurataTYamamotoSKawaguchiTKuboAIsaSIs consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non–small-cell lung cancer?: A pooled analysis of the literatureJ Thorac Oncol201381181910.1097/JTO.0b013e318298834823883782Open DOISearch in Google Scholar
Luo H, Yu X, Liang N, Xie J, Deng G, Liu Q, et al. The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy. Medicine 2017; 96: e6165. 10.1097/MD.0000000000006165LuoHYuXLiangNXieJDengGLiuQThe effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapyMedicine201796e616510.1097/MD.0000000000006165556943728225501Open DOISearch in Google Scholar
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-6. 10.1200/JCO.2007.14.4824KellyKChanskyKGasparLEAlbainKSJettJUngYCPhase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023J Clin Oncol2008262450610.1200/JCO.2007.14.482418378568Open DOISearch in Google Scholar
Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non–small-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015; 16: 340-7. 10.1016/j.cllc.2014.12.014WozniakAJMoonJThomasCRKellyKMackPCGasparLEA pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non–small-cell lung cancer: SWOG S0533Clin Lung Cancer201516340710.1016/j.cllc.2014.12.014449794125703100Open DOISearch in Google Scholar
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-pd-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol 2013; 86: 343-9. 10.1016/j.ijrobp.2012.12.025ZengJSeeAPPhallenJJacksonCMBelcaidZRuzevickJAnti-pd-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomasInt J Radiat Oncol201386343910.1016/j.ijrobp.2012.12.025Open DOISearch in Google Scholar
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-95. 10.1172/JCI67313DengLLiangHBurnetteBBeckettMDargaTWeichselbaumRRIrradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJ Clin Invest20141246879510.1172/JCI67313Open DOISearch in Google Scholar
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74: 5458-68. 10.1158/0008-5472.CAN-14-1258DovediSJAdlardALLipowska-BhallaGMcKennaCJonesSCheadleEJAcquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockadeCancer Res20147454586810.1158/0008.5472.CAN-14-1258Open DOISearch in Google Scholar
Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16: e498-509. 10.1016/S1470-2045(15)00007-8SharabiABLimMDeWeeseTLDrakeCG.Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergyLancet Oncol201516e49850910.1016/S1470-2045(15)00007-8Open DOISearch in Google Scholar
Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015; 3: 610-9. 10.1158/2326-6066.CIR-14-0138ParkSSDongHLiuXHarringtonSMKrcoCJGramsMPPD-1 restrains radiotherapy-induced abscopal effectCancer Immunol Res20153610910.1158/2326.6066.CIR-14-0138482771825701325Open DOISearch in Google Scholar
Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015; 356: 114-25. 10.1016/j.canlet.2013.08.024LumniczkyKSáfrányG.The impact of radiation therapy on the antitumor immunity: local effects and systemic consequencesCancer Lett20153561142510.1016/j.canlet.2013.08.02423994343Open DOISearch in Google Scholar
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1325. 10.1001/jamaoncol.2015.2756DemariaSGoldenEBFormentiSC.Role of local radiation therapy in cancer immunotherapyJAMA Oncol20151132510.1001/jamaoncol.2015.275626270858Open DOISearch in Google Scholar
Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 2016; 65: 779-86. 10.1007/s00262-015-1771-8DererAFreyBFietkauRGaiplUS.Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitorsCancer Immunol Immunother2016657798610.1007/s00262-015-1771-826590829Open DOISearch in Google Scholar
Fujimoto D, Uehara K, Sato Y, Sakanou I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 2017; 7: 11373. 10.1038/s41598-017-11949-9FujimotoDUeharaKSatoYSakanouIItoMTeraokaSAlteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patientsSci Rep201771137310.1038/s41598-017-11949-9559579628900290Open DOISearch in Google Scholar
Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996; 56: 5150-5.HallahanDKuchibhotlaJWybleC.Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endotheliumCancer Res19965651505Search in Google Scholar
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015; 3: 345-55. 10.1158/2326-6066.CIR-14-0196SharabiABNirschlCJKochelCMNirschlTRFrancicaBJVelardeEStereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigenCancer Immunol Res201533455510.1158/2326-6066CIR-14-0196439044425527358Open DOISearch in Google Scholar
Kachikwu EL, Iwamoto KS, Liao Y-P, DeMarco JJ, Agazaryan N, Economou J, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol 2011; 81: 1128-35. 10.1016/j.ijrobp.2010.09.034KachikwuELIwamotoKSLiaoY-PDeMarcoJJAgazaryanNEconomouJRadiation enhances regulatory T cell representationInt J Radiat Oncol20118111283510.1016/j.ijrobp.2010.09.034311795421093169Open DOISearch in Google Scholar
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-71. 10.1084/jem.20052494ReitsEAHodgeJWHerbertsCAGroothuisTAChakrabortyMK.WansleyERadiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJ Exp Med200620312597110.1084/jem.20052494321272716636135Open DOISearch in Google Scholar
Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti, SC, et al. TGF is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015; 75: 2232-42. 10.1158/0008-5472.CAN-14-3511Vanpouille-BoxCDiamondJMPilonesKAZavadilJBabbJSFormentiSCTGF is a master regulator of radiation therapy-induced antitumor immunityCancer Res20157522324210.1158/0008.5472.CAN-14-3511452215925858148Open DOISearch in Google Scholar
Velcheti V, Schalper Ka, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 2014; 94: 107-16. 10.1038/labinvest.2013.130VelchetiVSchalperKaCarvajalDEAnagnostouVKSyrigosKNSznolMProgrammed death ligand-1 expression in non-small cell lung cancerLab Investig2014941071610.1038/labinvest.2013.130612525024217091Open DOISearch in Google Scholar
Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015; 89: 181-8. 10.1016/j.lungcan.2015.05.007CooperWATranTVilainREMadoreJSelingerCIKohonen-CorishMPD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinomaLung Cancer201589181810.1016/j.lungcan.2015.05.00726024796Open DOISearch in Google Scholar
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysis. Eur J Surg Oncol 2015; 41: 450-6. 10.1016/j.ejso.2015.01.020WangAWangHYLiuYZhaoMCZhangHJLuZYThe prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysisEur J Surg Oncol201541450610.1016/j.ejso.2015.01.02025682184Open DOISearch in Google Scholar
Zhou Z, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2015; 4: 203-2082015; 4: 203-8. 10.3978/j.issn.2218-6751.2015.03.02ZhouZZhanPSongY.PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysisTransl Lung Cancer Res2015420320820154203810.3978/j.issn.2218.6751.2015.03.02438421225870804Open DOISearch in Google Scholar
Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7. 10.1038/nature14011HerbstRSSoriaJKowanetzMFineGDHamidOGordonMSPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515563710.1038/nature14011483619325428504Open DOISearch in Google Scholar
